Stocks and Investing
Stocks and Investing
Brian Abrahams Upgraded (BCRX) to Buy on, Jan 2nd, 2018
Brian Abrahams of RBC Capital, Upgraded "BioCryst Pharmaceuticals, Inc." (BCRX) to Buy on, Jan 2nd, 2018.
Brian has made no other calls on BCRX in the last 4 months.
There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Initiated at Hold and Held Target at $6 on, Wednesday, December 20th, 2017
These are the ratings of the 2 analyists that currently disagree with Brian
- Jessica Fye of "JP Morgan" Upgraded from Hold to Buy on, Wednesday, September 6th, 2017
- Maury Raycroft of "Jefferies" Upgraded from Hold to Strong Buy on, Wednesday, September 6th, 2017
Contributing Sources